Toril Holien

12PUBLICATIONS
36CO-AUTHORS
Biologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsBiomolecular modelling and designHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 17, 2026
Cell type-selective targeting by heterobifunctional protein binders via in-cell enrichment.

|Jun 27, 2024
Application of Photodynamic Therapy with 5-Aminolevulinic Acid to Extracorporeal Photopheresis in the Treatment of Cutaneous T-Cell Lymphoma: A First-in-Human Phase I/II Study.

Eidi Christensen, Olav Andreas Foss, Toril Holien

|Dec 03, 2021
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.

Katrine Melvold, Mariaserena Giliberto, Linda Karlsen

|Nov 25, 2021
Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides.

Jürgen M Kolos, Sebastian Pomplun, Sascha Jung

|Jul 08, 2020
Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis.

Aleksandr Ianevski, Evgeny Kulesskiy, Klara Krpina

|Apr 03, 2020
Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.

Oddrun Elise Olsen, Hanne Hella, Samah Elsaadi

Pageof 2

Frequent Collaborators

2 joint publications

Felix Hausch

1 joint publications

Oddrun Elise Olsen

1 joint publications

Meenu Sankar

1 joint publications

Kristine Misund